Castrate-resistant prostate cancer: therapeutic strategies.
Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies. This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors. The reader will gain an understanding of the therapies in development for castration-resistant disease. Therapies focused on multiple different targets are currently being studied for castrate-resistant prostate cancer.